Here’s what you should know:
1. Ardelyx is in the midst of several late-stage development programs. Tenapanor, its first-in-class irritable bowel syndrome with constipation treatment, leads its developmental pipeline.
2. Tenapanor is in phase III development. Ardelyx President and CEO Mike Raab said in a release the company is confident in the potential of the drug.
3. Mr. Raab said the layoffs align the company to “efficiently execute on our near-term milestones and to create value in the future.”
4. The company announced its second quarter financial data. Ardelyx has $148.7 million in total capital resources, a decrease from the $200.8 million it had as of Dec. 31, 2016.
5. Ardelyx posted a net loss of $25.7 million for the second quarter. It was an increase of $2.9 million year-over-year.
More articles on gastroenterology:
Allergan makes $4B in Q2 & more — 7 GI company key notes
GI leader to know: Dr. Scott Arlin of Ohio Gastroenterology Group
GI center to know: Ohio Gastroenterology Group
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
